KALA BIO, Inc. (NASDAQ:KALA) Stock Short Interest Report for SeptemberDefense World · Oct 12, 2026
KALA BIO (NASDAQ:KALA) Stock Falls 0.9% – Time to Sell?Defense World · Oct 11, 2026
KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since InceptionNewsfile Corp · Sep 29, 2026
Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing ProductsGlobeNewsWire · Sep 24, 2026
KALA BIO, Inc. (NASDAQ:KALA) Given Consensus Recommendation of “Reduce” by BrokeragesDefense World · Sep 18, 2026
KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory TeamGlobeNewsWire · Sep 17, 2026Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 19, 2026 | -$6.00 | -$21.32 | Miss |
| May 15, 2026 | -$8.50 | -$0.14 | Beat |
| Apr 15, 2026 | -$16.00 | $0.08 | Beat |
| Nov 19, 2025 | -$50.50 | -$1.07 | Beat |
| Aug 8, 2025 | -$91.00 | -$85.50 | Beat |
| May 14, 2025 | -$101.50 | -$70.50 | Beat |